Orchestra BioMed files secondary offering of ~8M shares
Source: SeekingAlpha
2025-11-03 05:47:53 ET
More on Orchestra BioMed
- Orchestra BioMed rises as trial for antihypertensive drug expands
- Seeking Alpha’s Quant Rating on Orchestra BioMed
- Historical earnings data for Orchestra BioMed
- Financial information for Orchestra BioMed
Read the full article on Seeking Alpha
For further details see:
Orchestra BioMed files secondary offering of ~8M shares
Orchestra BioMed Holdings Inc Com
NASDAQ: OBIO
OBIO Trading
2.17% G/L:
$4.70 Last:
81,060 Volume:
$4.70 Open:
OBIO Latest News
March 03, 2026 08:00:00 am
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
January 12, 2026 09:00:00 am
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
December 08, 2025 07:00:00 am
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
November 26, 2025 04:05:00 pm
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OBIO Stock Data
$235,457,928
31,902,573
2.32%
5
N/A
Biotechnology & Life Sciences
Healthcare
US
New Hope
